Literature DB >> 15332601

Immunohistological identification of receptor activator of NF-kappaB ligand (RANKL) in human, ovine and bovine bone tissues.

R J Mueller1, R G Richards.   

Abstract

Receptor activator of NF-kappaB ligand (RANKL, also called ODF/TRANCE/OPGL) is the final factor of osteoclast differentiation. Osteoclastogenesis may be determined by its receptor RANK and the relative ratio of RANKL to its decoy receptor osteoprotegerin (OPG), and alterations in this ratio may be a major cause of bone loss in many metabolic and immunologic disorders. In order to get a better insight into this complex regulatory system, this study aimed to determine where RANKL protein is located in bone tissues. RANKL was stained immunohistochemically in ex vivo human, ovine and bovine bone tissue. RANKL was observed labelled in the membrane of osteoblasts, osteocytes and osteoclasts and their surrounding matrix. In cartilage, which was used as a negative tissue control, chondrocytes were not stained. The presence of RANKL protein in the membrane of osteoblasts and also the secretion of RANKL by osteoclasts has been hypothesised in earlier studies. In this study, RANKL protein was shown histologically for the first time in the membrane and in the long processes of osteocytes. The result strongly suggests the crucial involvement of osteocytes in terms of orchestrating bone remodelling by influencing differentiation and activation of osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15332601     DOI: 10.1023/b:jmsm.0000021103.39114.cd

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  22 in total

1.  Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells.

Authors:  N Udagawa; N Takahashi; T Akatsu; H Tanaka; T Sasaki; T Nishihara; T Koga; T J Martin; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

2.  The cellular basis of bone turnover and bone loss: a rebuttal of the osteocytic resorption--bone flow theory.

Authors:  A M Parfitt
Journal:  Clin Orthop Relat Res       Date:  1977       Impact factor: 4.176

3.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

4.  Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

Authors:  K Matsuzaki; N Udagawa; N Takahashi; K Yamaguchi; H Yasuda; N Shima; T Morinaga; Y Toyama; Y Yabe; K Higashio; T Suda
Journal:  Biochem Biophys Res Commun       Date:  1998-05-08       Impact factor: 3.575

5.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

6.  Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.

Authors:  N Udagawa; N Takahashi; E Jimi; K Matsuzaki; T Tsurukai; K Itoh; N Nakagawa; H Yasuda; M Goto; E Tsuda; K Higashio; M T Gillespie; T J Martin; T Suda
Journal:  Bone       Date:  1999-11       Impact factor: 4.398

7.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.

Authors:  V Kartsogiannis; H Zhou; N J Horwood; R J Thomas; D K Hards; J M Quinn; P Niforas; K W Ng; T J Martin; M T Gillespie
Journal:  Bone       Date:  1999-11       Impact factor: 4.398

8.  Backscattered electron imaging of the undersurface of resin-embedded cells by field-emission scanning electron microscopy.

Authors:  R G Richards; I A Gwynn
Journal:  J Microsc       Date:  1995-01       Impact factor: 1.758

9.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

10.  TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.

Authors:  B R Wong; R Josien; S Y Lee; B Sauter; H L Li; R M Steinman; Y Choi
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

View more
  10 in total

1.  Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading.

Authors:  Lidan You; Sara Temiyasathit; Peling Lee; Chi Hyun Kim; Padmaja Tummala; Wei Yao; Wade Kingery; Amanda M Malone; Ronald Y Kwon; Christopher R Jacobs
Journal:  Bone       Date:  2007-09-26       Impact factor: 4.398

Review 2.  Intercellular cross-talk among bone cells: new factors and pathways.

Authors:  Natalie A Sims; Nicole C Walsh
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

3.  The enigmas of bone without osteocytes.

Authors:  Ron Shahar; Mason N Dean
Journal:  Bonekey Rep       Date:  2013-05-01

4.  Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations.

Authors:  Oran D Kennedy; Brad C Herman; Damien M Laudier; Robert J Majeska; Hui B Sun; Mitchell B Schaffler
Journal:  Bone       Date:  2012-02-09       Impact factor: 4.398

Review 5.  Relationship between serum RANKL and RANKL in bone.

Authors:  D M Findlay; G J Atkins
Journal:  Osteoporos Int       Date:  2011-08-18       Impact factor: 4.507

6.  Alterations in the osteocyte lacunar-canalicular microenvironment due to estrogen deficiency.

Authors:  Divya Sharma; Cesare Ciani; Paula A Ramirez Marin; Jessica D Levy; Stephen B Doty; Susannah P Fritton
Journal:  Bone       Date:  2012-05-23       Impact factor: 4.398

7.  Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association.

Authors:  Anthony Martin; Jian Xiong; Theodora Koromila; Jie S Ji; Stephanie Chang; Yae S Song; Jonathan L Miller; Chun-Ya Han; Paul Kostenuik; Susan A Krum; Nyam-Osor Chimge; Yankel Gabet; Baruch Frenkel
Journal:  Bone       Date:  2015-02-17       Impact factor: 4.398

8.  Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.

Authors:  Asiri R Wijenayaka; Masakazu Kogawa; Hui Peng Lim; Lynda F Bonewald; David M Findlay; Gerald J Atkins
Journal:  PLoS One       Date:  2011-10-04       Impact factor: 3.240

9.  Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading.

Authors:  Takeshi Moriishi; Ryo Fukuyama; Masako Ito; Toshihiro Miyazaki; Takafumi Maeno; Yosuke Kawai; Hisato Komori; Toshihisa Komori
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  Relationships between the Bone Expression of Alzheimer's Disease-Related Genes, Bone Remodelling Genes and Cortical Bone Structure in Neck of Femur Fracture.

Authors:  Catherine J M Stapledon; Roumen Stamenkov; Roberto Cappai; Jillian M Clark; Alice Bourke; L Bogdan Solomon; Gerald J Atkins
Journal:  Calcif Tissue Int       Date:  2021-01-04       Impact factor: 4.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.